139 related articles for article (PubMed ID: 36322814)
1. Tailoring Two Chemometric Models for Determination of Three Neuromuscular Combined Medications and Application to Spiked Human Plasma.
Abdelhamid NS; Farid NF; Anwar BH; Magdy MA
J AOAC Int; 2023 May; 106(3):786-793. PubMed ID: 36322814
[TBL] [Abstract][Full Text] [Related]
2. A validated ecofriendly chromatographic method for determination of myasthenia gravis combined medications in spiked human plasma.
Magdy MA; Farid NF; Anwar BH; Abdelhamid NS
Biomed Chromatogr; 2023 Jun; 37(6):e5615. PubMed ID: 36882891
[TBL] [Abstract][Full Text] [Related]
3. Multivariate Model Update Chemometric Methods for Determination of Prednisolone and Esomeprazole in Spiked Human Plasma: A Comparative Study.
Farid NF; Magdy MA; Anwar BH; Abdelhamid NS
J AOAC Int; 2022 Feb; 105(1):317-322. PubMed ID: 34478551
[TBL] [Abstract][Full Text] [Related]
4. Smart Multivariate Spectrophotometric Determination of Two Co-Administered Autoimmune Drugs; Sulfasalazine and Pentoxifylline; in Bulk and Spiked Human Plasma.
Magdy MA; Farid NF; Anwar BH; Abdelhamid NS
J AOAC Int; 2024 Jan; 107(1):189-195. PubMed ID: 37610330
[TBL] [Abstract][Full Text] [Related]
5. US FDA-validated TLC method with four greenness assessment evaluations for simultaneous determination of prednisolone and esomeprazole in spiked human plasma.
Abdelhamid NS; Magdy MA; Anwar BH; Farid NF
Biomed Chromatogr; 2022 May; 36(5):e5343. PubMed ID: 35062043
[TBL] [Abstract][Full Text] [Related]
6. Chemometric Assisted UV-Spectrophotometric Methods Using Multivariate Curve Resolution Alternating Least Squares and Partial Least Squares Regression for Determination of Beta-Antagonists in Formulated Products: Evaluation of the Ecological Impact.
Mostafa A; Shaaban H
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615522
[TBL] [Abstract][Full Text] [Related]
7. Plasma pyridostigmine levels in myasthenia gravis.
White MC; De Silva P; Havard CW
Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
[TBL] [Abstract][Full Text] [Related]
8. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis.
Davison SC; Hyman NM; Dehghan A; Chan K
J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1141-5. PubMed ID: 7334410
[TBL] [Abstract][Full Text] [Related]
9. Long term treatment of myasthenia gravis with azathioprine.
Fonseca V; Havard CW
Postgrad Med J; 1990 Feb; 66(772):102-5. PubMed ID: 2112245
[TBL] [Abstract][Full Text] [Related]
10. Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.
Lorenzoni PJ; Kay CSK; Ducci RD; Fustes OJH; Werneck LC; Scola RH
Arq Neuropsiquiatr; 2020 Mar; 78(3):179-181. PubMed ID: 32215460
[TBL] [Abstract][Full Text] [Related]
11. Determination of erythrocyte-bound acetylcholinesterase activity for monitoring pyridostigmine therapy in myasthenia gravis.
Henze T; Nenner M; Michaelis HC
J Neurol; 1991 Jul; 238(4):225-9. PubMed ID: 1895153
[TBL] [Abstract][Full Text] [Related]
12. Adjusted green spectrophotometric determination of favipiravir and remdesivir in pharmaceutical form and spiked human plasma sample using different chemometric supported models.
Imam MS; Abdelazim AH; Ramzy S; Batubara AS; Gamal M; Abdelhafiz S; Zeid AM
BMC Chem; 2023 Jul; 17(1):89. PubMed ID: 37501208
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
14. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
15. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
[TBL] [Abstract][Full Text] [Related]
16. A green spectrophotometric method for the simultaneous determination of nasal binary mixture used in respiratory diseases: Applying isosbestic point and chemometric approaches as a resolving tool, greenness evaluation.
Fawzy MG; Saleh H; Reda A; Bahgat EA
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Dec; 283():121585. PubMed ID: 35988471
[TBL] [Abstract][Full Text] [Related]
17. Presentation of myasthenia gravis mimicking blepharospasm.
Roberts ME; Steiger MJ; Hart IK
Neurology; 2002 Jan; 58(1):150-1. PubMed ID: 11781428
[No Abstract] [Full Text] [Related]
18. Determination of Gemcitabine and Sorafenib in Spiked Human Plasma Using Multivariate Model Update Chemometric Methods.
Sharkawi MMZ; Mohamed NR; El-Saadi MT; Amin NH
J AOAC Int; 2023 Nov; 106(6):1666-1672. PubMed ID: 37233147
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation.
Batubara AS; Abdelazim AH; Almrasy AA; Gamal M; Ramzy S
BMC Chem; 2023 Jun; 17(1):58. PubMed ID: 37328879
[TBL] [Abstract][Full Text] [Related]
20. Decompensating esophoria as the presenting feature of myasthenia gravis.
Arblaster GE; Shipman TL; Pepper IM
J AAPOS; 2009 Jun; 13(3):310-1. PubMed ID: 19395293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
